Company Filing History:
Years Active: 2013
Title: Jiwen Chen: Innovator in Cancer Treatment
Introduction
Jiwen Chen, based in Bridgewater, NJ, has made significant contributions to the field of cancer treatment through his innovative work in biomarker research. With a keen focus on enhancing therapeutic responses, his patent represents a crucial advancement in the identification and monitoring of patients who may benefit from insulin growth factor-1 receptor (IGF1R) modulators.
Latest Patents
Jiwen Chen holds a patent titled "Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators." This patent presents methods utilizing IGF1R biomarkers to identify and monitor mammals, particularly in the context of cancer treatment. The process involves administering an IGF1R modulator to a mammal and measuring biomarker levels to assess therapeutic responses. A significant difference in biomarker levels before and after exposure indicates the mammal's potential response to cancer treatment, showcasing Chen's innovative approach to personalized medicine.
Career Highlights
Jiwen Chen's career is marked by his association with Bristol Myers Squibb Company, a leading pharmaceutical firm known for its focus on innovative medicines. Throughout his tenure, he has dedicated his efforts to researching cancer therapies that leverage the body's biological markers, which has earned him recognition in the scientific community.
Collaborations
Collaborating with esteemed colleagues such as Fei Huang and Xia Han, Jiwen Chen has contributed to a collaborative research environment that emphasizes the value of teamwork in medical innovations. Their combined efforts aim to enhance therapeutic strategies that can effectively combat cancer, demonstrating the importance of interdisciplinary partnerships in medical research.
Conclusion
Jiwen Chen's work exemplifies the impact of innovation in the medical field, particularly in the realm of cancer treatment. Through his patented research on IGF1R biomarkers, he has paved the way for more effective therapeutic methods, marking a significant step forward in personalized medicine. As he continues his work at Bristol Myers Squibb Company, Chen remains at the forefront of innovation, dedicated to improving patient outcomes in oncology.